Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy

被引:6
|
作者
Kang, Seung Hyun [1 ]
Lee, Chang-Han [1 ,2 ,3 ,4 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea
[3] SNU, Wide River Inst Immunol WRII, Hongcheon 25159, South Korea
[4] Seoul Natl Univ, Coll Med, SNU Dementia Res Ctr, Seoul 03080, South Korea
关键词
therapeutic antibody; antibody engineering; Fc engineering; bispecific antibody; FC-GAMMA RECEPTORS; MEMORY B-CELLS; MONOCLONAL-ANTIBODIES; IN-VIVO; ENGINEERED ANTIBODY; R-BINDING; HALF-LIFE; CLINICAL DEVELOPMENT; AFFINITY MATURATION; EFFECTOR FUNCTIONS;
D O I
10.1007/s12257-020-0181-8
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Monoclonal antibodies (mAb) have been used as therapeutic agents for various diseases, and immunoglobulin G (IgG) is mainly used among antibody isotypes due to its structural and functional properties. So far, regardless of the purpose of the therapeutic antibody, wildtype IgG has been mainly used, but recently, the engineered antibodies with various strategies according to the role of the therapeutic antibody have been used to maximize the therapeutic efficacy. In this review paper, first, the overall structural features and functional characteristics of antibody IgG, second, the old and new techniques for antibody discovery, and finally, several antibody engineering strategies for maximizing therapeutic efficacy according to the role of a therapeutic antibody will be introduced.
引用
收藏
页码:295 / 311
页数:17
相关论文
共 50 条
  • [1] Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy
    Seung Hyun Kang
    Chang-Han Lee
    Biotechnology and Bioprocess Engineering, 2021, 26 : 295 - 311
  • [2] Development of therapeutic antibodies for the treatment of diseases
    Lu, Ruei-Min
    Hwang, Yu-Chyi
    Liu, I-Ju
    Lee, Chi-Chiu
    Tsai, Han-Zen
    Li, Hsin-Jung
    Wu, Han-Chung
    JOURNAL OF BIOMEDICAL SCIENCE, 2020, 27 (01)
  • [3] Antibody engineering for the development of therapeutic antibodies
    Kim, SJ
    Park, Y
    Hong, HJ
    MOLECULES AND CELLS, 2005, 20 (01) : 17 - 29
  • [4] Engineering therapeutic monoclonal antibodies
    Stone, Cosby A.
    Spiller, Benjamin W.
    Smith, Scott A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (03) : 539 - 548
  • [5] Modified Therapeutic Antibodies: Improving Efficacy
    Dai, Ji-Min
    Zhang, Xue-Qin
    Dai, Jing-Yao
    Yang, Xiang-Min
    Chen, Zhi-Nan
    ENGINEERING, 2021, 7 (11) : 1529 - 1540
  • [6] Fc Engineering to Improve the Function of Therapeutic Antibodies
    Mimoto, Futa
    Kuramochi, Taichi
    Katada, Hitoshi
    Igawa, Tomoyuki
    Hattori, Kunihiro
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2016, 17 (15) : 1298 - 1314
  • [7] Pharmacokinetic characteristics of therapeutic antibodies
    Wohlrab, Johannes
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 (06): : 530 - 534
  • [8] Development of therapeutic antibodies for the treatment of diseases
    Ruei-Min Lu
    Yu-Chyi Hwang
    I-Ju Liu
    Chi-Chiu Lee
    Han-Zen Tsai
    Hsin-Jung Li
    Han-Chung Wu
    Journal of Biomedical Science, 27
  • [9] Antibody modulation: Limiting the efficacy of therapeutic antibodies
    Vaughan, Andrew T.
    Cragg, Mark S.
    Beers, Stephen A.
    PHARMACOLOGICAL RESEARCH, 2015, 99 : 269 - 275
  • [10] Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering
    Haraya, Kenta
    Tachibana, Tatsuhiko
    Igawa, Tomoyuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : 25 - 41